

  <!doctype html>
<html lang="en-US">

<!-- Mirrored from www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:41:09 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
    <link rel="profile" href="https://gmpg.org/xfn/11">
    <link rel="preload" as="font" type="font/woff2" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_W_Wght.woff2" crossorigin="anonymous">
<link rel="preload" as="font" type="font/woff2" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_Italics_W_Wght.woff2" crossorigin="anonymous">    <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' />

	<!-- This site is optimized with the Yoast SEO plugin v18.2 - https://yoast.com/wordpress/plugins/seo/ -->
	<title>FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review - Merck.com</title>
	<link rel="canonical" href="https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/" />
	<meta property="og:locale" content="en_US" />
	<meta property="og:type" content="article" />
	<meta property="og:title" content="FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review - Merck.com" />
	<meta property="og:description" content="AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent. A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020. The sNDA acceptance for review by the FDA is based on positive results from the Phase 3 PROfound trial, which were presented during a Presidential Symposium at the 2019 European Society of Medical Oncology congress. Results of the PROfound trial showed LYNPARZA met its primary endpoint, significantly reducing the risk of radiographic disease progression or death by 66% in" />
	<meta property="og:url" content="https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/" />
	<meta property="og:site_name" content="Merck.com" />
	<meta property="article:modified_time" content="2022-10-04T04:06:22+00:00" />
	<meta property="og:image" content="https://www.businesswire.com/images/spacer.gif" />
	<meta name="twitter:card" content="summary_large_image" />
	<meta name="twitter:label1" content="Est. reading time" />
	<meta name="twitter:data1" content="15 minutes" />
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"https://www.merck.com/#website","url":"https://www.merck.com/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.merck.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/#primaryimage","inLanguage":"en-US","url":"https://www.businesswire.com/images/spacer.gif","contentUrl":"https://www.businesswire.com/images/spacer.gif"},{"@type":"WebPage","@id":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/#webpage","url":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/","name":"FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review - Merck.com","isPartOf":{"@id":"https://www.merck.com/#website"},"primaryImageOfPage":{"@id":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/#primaryimage"},"datePublished":"2020-01-21T06:55:00+00:00","dateModified":"2022-10-04T04:06:22+00:00","breadcrumb":{"@id":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/"]}]},{"@type":"BreadcrumbList","@id":"https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://www.merck.com/news-archive/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review"}]}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel='dns-prefetch' href='http://s.w.org/' />
<link rel='dns-prefetch' href='http://v0.wordpress.com/' />
<link rel='stylesheet' id='single-news-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/single-news_item.min.css?ver=20200302' media='all' />
<link rel='stylesheet' id='wp-block-library-css'  href='https://www.merck.com/wp-includes/css/dist/block-library/style.min.css?ver=5.9.4' media='all' />
<style id='wp-block-library-inline-css'>
.has-text-align-justify{text-align:justify;}
</style>
<link rel='stylesheet' id='mediaelement-css'  href='https://www.merck.com/wp-includes/js/mediaelement/mediaelementplayer-legacy.min.css?ver=4.2.16' media='all' />
<link rel='stylesheet' id='wp-mediaelement-css'  href='https://www.merck.com/wp-includes/js/mediaelement/wp-mediaelement.min.css?ver=5.9.4' media='all' />
<link rel='stylesheet' id='elasticpress-related-posts-block-css'  href='https://www.merck.com/wp-content/mu-plugins/search/elasticpress/dist/css/related-posts-block-styles.min.css?ver=3.6.5' media='all' />
<style id='global-styles-inline-css'>
body{--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel='stylesheet' id='all-css-12' href='https://www.merck.com/wp-content/plugins/seriously-simple-podcasting/assets/css/recent-episodes.css?m=1664556542g' type='text/css' media='all' />
<link rel='stylesheet' id='qm-objectcache-style-css'  href='https://www.merck.com/wp-content/mu-plugins/qm-plugins/qm-object-cache/css/style.css?ver=0.1' media='all' />
<link rel='stylesheet' id='Mco-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/style.min.css?ver=20190301' media='all' />
<link rel="https://api.w.org/" href="https://www.merck.com/wp-json/" /><link rel="alternate" type="application/json" href="https://www.merck.com/wp-json/wp/v2/news_item/744019" /><link rel='shortlink' href='https://www.merck.com/?p=744019' />
<link rel="alternate" type="application/json+oembed" href="https://www.merck.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review%2F" />
<link rel="alternate" type="text/xml+oembed" href="https://www.merck.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review%2F&amp;format=xml" />

<link rel="alternate" type="application/rss+xml" title="Podcast RSS feed" href="https://www.merck.com/feed/podcast" />

<script type="text/javascript">
var dataLayer = dataLayer || [];
dataLayer.push({"user":{"role":"visitor","isLoggedIn":false}});
dataLayer.push({"site":[]});
dataLayer.push({"page":{"page_wpid":"744019","page_language":"en_us","page_lineofbusiness":"human health","page_accessibility":"publish","page_title":"fda accepts regulatory submission of supplemental new drug application for lynparza\u00ae (olaparib) in hrr-mutated metastatic castration-resistant prostate cancer and grants priority review"}});
</script>
<script type="text/javascript">
(
        function( w, d, s, l, i ) {
            w[l] = w[l] || [];
            w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
					var f = d.getElementsByTagName( s )[0],
						j = d.createElement( s ), dl = l !== 'dataLayer' ? '&l=' + l : '';
					j.async = true;
					j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
					f.parentNode.insertBefore( j, f );
				}
        )( window, document, 'script', 'dataLayer', 'GTM-M74WZDM' );
</script>
<meta name="page_wpid" content="744019" /><meta name="page_language" content="en_US" /><meta name="page_lineofbusiness" content="Human Health" /><meta name="page_accessibility" content="publish" /><meta name="page_title" content="fda accepts regulatory submission of supplemental new drug application for lynparza® (olaparib) in hrr-mutated metastatic castration-resistant prostate cancer and grants priority review" />        <link rel="apple-touch-icon" sizes="180x180" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon-16x16.png">

    <link rel="manifest" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site.webmanifest">
    <link rel="mask-icon" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/safari-pinned-tab.svg" color="#ffffff">
    <link rel="shortcut icon" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon.ico">
    <meta name="msapplication-TileColor" content="#ffffff">
    <meta name="msapplication-config" content="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/browserconfig.xml">
    <meta name="theme-color" content="#ffffff">
    
<style>
    :root {
        --colorTextPrimary: #000000;
        --colorPrimary: #00857C;
        --colorPrimaryLight: #6ECEB2;
        --colorPrimaryDark: #005C55;
        --colorPrimaryDarkBlue: #0C2340;
        --colorSecondaryLime: #BFED33;
        --colorSecondaryLemon: #FFF063;
        --colorSecondaryPastelBlue: #69B8F7;
        --colorSecondaryVistaBlue: #688CE8;
        --colorSecondaryRichBlue: #5450E4;
        --colorBlack: #000000;
        --colorWhite: #FFFFFF;
        --colorOffWhite: #F7F7F7;
        --colorGray: #757575;
        --colorWarning: #FE0000;
        --colorSuccess: #029A01;
        --colorInfo: #1058A4;
        --colorGrayHRTwenty: #75757533;
        --colorGrayHRTen: #7575751a;
    }
</style> </head>

<body class="news_item-template-default single single-news_item postid-744019 no-sidebar">
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M74WZDM&amp;user%5Brole%5D=visitor&amp;user%5BisLoggedIn%5D=0&amp;page%5Bpage_wpid%5D=744019&amp;page%5Bpage_language%5D=en_us&amp;page%5Bpage_lineofbusiness%5D=human%20health&amp;page%5Bpage_accessibility%5D=publish&amp;page%5Bpage_title%5D=fda%20accepts%20regulatory%20submission%20of%20supplemental%20new%20drug%20application%20for%20lynparza%c2%ae%20(olaparib)%20in%20hrr-mutated%20metastatic%20castration-resistant%20prostate%20cancer%20and%20grants%20priority%20review" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-dark-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0.49803921568627" /><feFuncG type="table" tableValues="0 0.49803921568627" /><feFuncB type="table" tableValues="0 0.49803921568627" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.54901960784314 0.98823529411765" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.71764705882353 0.25490196078431" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-red"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 0.27843137254902" /><feFuncB type="table" tableValues="0.5921568627451 0.27843137254902" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-midnight"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0" /><feFuncG type="table" tableValues="0 0.64705882352941" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-magenta-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.78039215686275 1" /><feFuncG type="table" tableValues="0 0.94901960784314" /><feFuncB type="table" tableValues="0.35294117647059 0.47058823529412" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-green"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.65098039215686 0.40392156862745" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.44705882352941 0.4" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-orange"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.098039215686275 1" /><feFuncG type="table" tableValues="0 0.66274509803922" /><feFuncB type="table" tableValues="0.84705882352941 0.41960784313725" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><div id="page" class="site">
    <a class="skip-link screen-reader-text" href="#content">Skip to content</a>

    

    <header id="masthead" class="site-header">
                <nav id="site-navigation" class="main-navigation">
            <div class="wrapper header-wrapper">
                <div class="site-branding">
            <p class="site-title">
                <a href="https://www.merck.com/" rel="home" title="Merck.com">
            <img class="site-logo" src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/logo.jpeg" alt="Site logo" />
            </a>
            </p>
    </div><!-- .site-branding -->                <div id="mastheadMenu">
    <button id="siteSearchToggle" class="btn" aria-controls="primary-search" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/search-white.svg" alt="menu icon" />
            <span>Search everything</span>
        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
    <button id="siteNavigationToggle" class="btn menu-toggle" aria-controls="primary-menu" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/burger-white.svg" alt="menu icon" />Menu        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
</div>            </div><!-- .header-wrapper -->
        </nav><!-- #site-navigation -->
        <nav id="site-menu" class="main-menu">
	<div class="wrapper">
		<a class="menucrumb" href="#">Main menu</a>
		<div class="menu-main-menu-container"><ul id="menuMain" class="menu-main level-0 menu-open"><li id="menu-item-666469" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666469"><a href="https://www.merck.com/company-overview/">Company</a>
<ul class="level-1">
	<li id="menu-item-666471" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666471"><a href="https://www.merck.com/company-overview/">Company overview</a></li>
	<li id="menu-item-667007" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667007"><a href="https://www.merck.com/stories/">Stories</a></li>
	<li id="menu-item-2773656" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2773656"><a href="https://www.merck.com/company-overview/history/">History</a></li>
	<li id="menu-item-666473" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666473"><a href="https://www.merck.com/company-overview/esg/">Environmental, Social &#038; Governance (ESG)</a>
	<ul class="level-2">
		<li id="menu-item-2388650" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388650"><a href="https://www.merck.com/company-overview/esg/">ESG overview</a></li>
		<li id="menu-item-2388653" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388653"><a href="https://www.merck.com/company-overview/esg/philanthropy/">Philanthropy</a></li>
		<li id="menu-item-2796573" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2796573"><a href="https://www.merck.com/company-overview/esg/merck-medical-outreach-program/">Merck Medical Outreach Program</a></li>
		<li id="menu-item-2798027" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2798027"><a href="https://www.merck.com/company-overview/esg/impact-investing/">Impact investing</a></li>
		<li id="menu-item-2804132" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2804132"><a href="https://www.merck.com/company-overview/esg/transparency-disclosures/">Transparency disclosures</a></li>
		<li id="menu-item-2808199" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2808199"><a href="https://www.merck.com/company-overview/esg/esg-resources/">ESG resources</a></li>
	</ul>
</li>
	<li id="menu-item-666474" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666474"><a href="https://www.merck.com/company-overview/leadership/">Leadership</a>
	<ul class="level-2">
		<li id="menu-item-666483" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666483"><a href="https://www.merck.com/company-overview/leadership/">Leadership overview</a></li>
		<li id="menu-item-666484" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666484"><a href="https://www.merck.com/company-overview/leadership/board-of-directors/">Board of directors</a></li>
		<li id="menu-item-666485" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666485"><a href="https://www.merck.com/company-overview/leadership/executive-team/">Executive team</a></li>
	</ul>
</li>
	<li id="menu-item-666475" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666475"><a href="https://www.merck.com/company-overview/culture-and-values/">Culture &amp; values</a>
	<ul class="level-2">
		<li id="menu-item-666488" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666488"><a href="https://www.merck.com/company-overview/culture-and-values/">Culture &#038; values overview</a></li>
		<li id="menu-item-666489" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666489"><a href="https://www.merck.com/company-overview/culture-and-values/code-of-conduct/">Code of conduct &amp; compliance</a></li>
	</ul>
</li>
	<li id="menu-item-666476" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666476"><a href="https://www.merck.com/company-overview/diversity-and-inclusion/">Diversity &amp; inclusion</a></li>
	<li id="menu-item-666477" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666477"><a href="https://www.merck.com/company-overview/policies-and-positions/">Policies &amp; positions</a></li>
	<li id="menu-item-666478" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666478"><a href="https://www.merck.com/company-overview/business-development-licensing/">Business development &amp; licensing</a></li>
	<li id="menu-item-666479" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666479"><a href="https://www.merck.com/company-overview/suppliers/">Suppliers</a>
	<ul class="level-2">
		<li id="menu-item-667793" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667793"><a href="https://www.merck.com/company-overview/suppliers/">Suppliers overview</a></li>
		<li id="menu-item-667792" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-667792"><a target="_blank" rel="noopener" href="https://msd.quantumsds.com/">Supplier registration</a></li>
		<li id="menu-item-3601080" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3601080"><a href="https://suppliers.msd.com/">Supplier help for Ariba</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-14540" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-14540"><a href="https://www.merck.com/research/">Research</a>
<ul class="level-1">
	<li id="menu-item-666505" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666505"><a href="https://www.merck.com/research/">Research overview</a></li>
	<li id="menu-item-2388262" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-2388262"><a href="https://www.merck.com/research/covid-19/">Our COVID-19 efforts</a></li>
	<li id="menu-item-666527" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666527"><a target="_blank" rel="noopener" href="#">Areas of focus</a>
	<ul class="level-2">
		<li id="menu-item-666509" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666509"><a href="https://www.merck.com/research/oncology/">Oncology</a></li>
		<li id="menu-item-666507" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666507"><a href="https://www.merck.com/research/vaccines/">Vaccines</a></li>
		<li id="menu-item-666508" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666508"><a href="https://www.merck.com/research/infectious-diseases/">Infectious diseases</a></li>
		<li id="menu-item-666510" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666510"><a href="https://www.merck.com/research/cardio-metabolic-disorders/">Cardio-metabolic disorders</a></li>
	</ul>
</li>
	<li id="menu-item-666511" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666511"><a href="https://www.merck.com/research/product-pipeline/">Pipeline</a></li>
	<li id="menu-item-666512" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666512"><a href="https://www.merck.com/research/discovery-development/">Discovery &amp; development</a></li>
	<li id="menu-item-3600289" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3600289"><a href="https://www.merck.com/research/rd-locations/">R&#038;D locations</a></li>
	<li id="menu-item-666513" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666513"><a href="https://www.merck.com/research/clinical-trials/">Clinical trials</a>
	<ul class="level-2">
		<li id="menu-item-666673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666673"><a href="https://www.merck.com/research/clinical-trials/">Clinical trials overview</a></li>
		<li id="menu-item-666672" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-666672"><a target="_blank" rel="noopener" href="https://www.merckclinicaltrials.com/">Find a trial</a></li>
		<li id="menu-item-2805336" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2805336"><a href="https://www.merck.com/research/diversity-in-clinical-trials/">Diversity in clinical trials</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-3600254" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3600254"><a href="https://www.merck.com/products/">Products</a>
<ul class="level-1">
	<li id="menu-item-666506" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666506"><a href="https://www.merck.com/products/">Products list</a></li>
	<li id="menu-item-666515" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666515"><a href="https://www.merck.com/products/patent/">Product patents</a></li>
	<li id="menu-item-14541" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14541"><a href="https://www.merck.com/products/distributors/">Merck authorized distributors</a></li>
</ul>
</li>
<li id="menu-item-628574" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-628574"><a href="https://www.merck.com/patients/">Patients</a>
<ul class="level-1">
	<li id="menu-item-2784133" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2784133"><a href="https://www.merck.com/patients/">Patients overview</a></li>
	<li id="menu-item-2181846" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2181846"><a href="https://www.merck.com/patients/patient-financial-assistance/">Patient support programs</a></li>
	<li id="menu-item-628576" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628576"><a href="https://www.merck.com/patients/patient-resources/">Patient resources</a></li>
	<li id="menu-item-628575" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628575"><a href="https://www.merck.com/patients/patient-and-treatment-education/">Patient &amp; treatment education</a></li>
</ul>
</li>
<li id="menu-item-666493" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666493"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en">Careers</a>
<ul class="level-1">
	<li id="menu-item-696146" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696146"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/home">Careers</a></li>
	<li id="menu-item-696145" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696145"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/search-results">Search jobs</a></li>
	<li id="menu-item-696144" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-696144"><a href="#">Our divisions</a>
	<ul class="level-2">
		<li id="menu-item-696175" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696175"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/research-laboratories">Research &#038; development</a></li>
		<li id="menu-item-696174" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696174"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/manufacturing">Manufacturing &#038; supply</a></li>
		<li id="menu-item-696172" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696172"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/human-health">Human Health</a></li>
		<li id="menu-item-696171" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696171"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/animal-health">Animal Health</a></li>
		<li id="menu-item-696164" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696164"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/global-support-functions">Global support functions</a></li>
	</ul>
</li>
	<li id="menu-item-696141" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696141"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/veteran-opportunities">Veterans</a></li>
	<li id="menu-item-696140" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696140"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/student-opportunities">Student opportunities</a></li>
	<li id="menu-item-696139" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696139"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/compensation-and-benefits">Compensation &#038; benefits</a></li>
	<li id="menu-item-696138" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696138"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/hiring-process">How we hire</a></li>
	<li id="menu-item-696137" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696137"><a target="_blank" rel="noopener" href="https://jobs.msd.com/gb/en/home">MSD Careers</a></li>
	<li id="menu-item-696136" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696136"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/events">Events</a></li>
	<li id="menu-item-696134" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696134"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/jointalentcommunity?applyType=JTC">Talent community</a></li>
</ul>
</li>
<li id="menu-item-137022" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-137022"><a href="https://www.merck.com/investor-relations/">Investors</a>
<ul class="level-1">
	<li id="menu-item-223087" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-223087"><a href="https://www.merck.com/investor-relations/">Investors overview</a></li>
	<li id="menu-item-220674" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220674"><a href="https://www.merck.com/investor-relations/events-and-presentations/">Events &amp; presentations</a></li>
	<li id="menu-item-220673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220673"><a href="https://www.merck.com/investor-relations/financial-information/">Financial information</a>
	<ul class="level-2">
		<li id="menu-item-666494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666494"><a href="https://www.merck.com/investor-relations/financial-information/">Financial information overview</a></li>
		<li id="menu-item-666495" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666495"><a href="https://www.merck.com/investor-relations/financial-information/sec-filings/">SEC filings</a></li>
	</ul>
</li>
	<li id="menu-item-220672" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220672"><a href="https://www.merck.com/investor-relations/stock-info/">Stock information</a></li>
	<li id="menu-item-220671" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220671"><a href="https://www.merck.com/investor-relations/investor-resources/">Investor resources</a>
	<ul class="level-2">
		<li id="menu-item-666496" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666496"><a href="https://www.merck.com/investor-relations/investor-resources/">Investor resources overview</a></li>
		<li id="menu-item-2793045" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2793045"><a href="https://www.merck.com/investor-relations/organon-resources/">Organon resources</a></li>
		<li id="menu-item-666497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666497"><a href="https://www.merck.com/investor-relations/investor-resources/information-request/">Request for information</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-650872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-650872"><a href="https://www.merck.com/media/">Media</a>
<ul class="level-1">
	<li id="menu-item-650874" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650874"><a href="https://www.merck.com/media/">Media overview</a></li>
	<li id="menu-item-650878" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650878"><a href="https://www.merck.com/media/news/">News releases</a></li>
	<li id="menu-item-650884" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650884"><a href="https://www.merck.com/media/company-statements/">Company statements</a></li>
	<li id="menu-item-3544562" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3544562"><a href="https://www.merck.com/media/media-library/">Media library &amp; contacts</a>
	<ul class="level-2">
		<li id="menu-item-3544537" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3544537"><a href="https://www.merck.com/media/media-library/">Media contact &#038; library overview</a></li>
		<li id="menu-item-650879" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650879"><a href="https://www.merck.com/media/media-library/company-fact-sheet/">Company fact sheet</a></li>
	</ul>
</li>
</ul>
</li>
</ul></div>		<div class="side-section">
															<div class="image">
						<picture>
							<source media="(max-width: 1279px)"
								data-srcset="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=370,418">
							<source media="(min-width: 1280px)"
								data-srcset="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=486,432">
							<img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=486,432" alt="two scientists wearing masks">
						</picture>
					</div>
													<div class="tagline"></div>
													<h4>Our COVID-19 efforts</h4>
													<a class="btn" href="https://www.merck.com/research/covid-19/" title="Learn more" target="">Learn more</a>
									</div>
		<div class="bottom-section">
			<a class="btn" href="https://www.merck.com/contact-us/">Contact us</a>
			<p>
				<a href="https://www.msd.com/contact-us/worldwide-locations/" target="_blank" rel="noopener">Worldwide</a>
				<small>Countries outside of the United States and Canada.</small>
			</p>
		</div>
	</div>
</nav><!-- #site-menu -->

        <form id="site-search" role="search" method="get" class="search-form" action="https://www.merck.com/" autocomplete="off">
    <h1>What can we help you find?</h1>
    <div id="site-search-box" class="input-box autocomplete">
        <span class="screen-reader-text">Search for:</span>
        <input type="text" class="search-field autocomplete-input" placeholder="Search here …" value="" name="s" aria-label="Search site">
        <button type="submit" class="submit search-submit"></button>
    </div>
    <div id="search_suggestion_result"></div> 
    </form>


<script>
    theme_directory = "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme";  
</script>
    </header><!-- #masthead -->
    <div id="content" class="site-content">


	<div id="primary" class="content-area">
                    <div class="breadcrumbs wrapper text-descriptive">
                <span>
                    <span>
                        <a href="https://www.merck.com/media/">
                            Media
                        </a> &gt; 
                        <span>
                            <a href="https://www.merck.com/media/news/">
                                News releases
                            </a> &gt; 
                            <span class="breadcrumb_last" aria-current="page">
                                News release
                            </span>
                        </span>
                    </span>
                </span>
            </div>
        		<main id="main" class="site-main single-news_item">
            <article id="post-744019" class="post-744019 news_item type-news_item status-publish hentry tag-corporate-news tag-latest-news tag-oncology tag-press-release">

                <div class="entry-content">
                    <div class="news-itm-header-container wrapper">
                        <div>
                            <h2 class="entry-title">
                                FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review                            </h2>
                        </div>
                    </div>

                    <div class="wrapper">
                        <div class="entry-header-links-div">
                                                        <a id="btnSave2PDF" href="https://s2.q4cdn.com/584635680/files/doc_news/FDA-Accepts-Regulatory-Submission-of-Supplemental-New-Drug-Application-for-LYNPARZA-olaparib-in-HRR-Mutated-Metastatic-Castration-Res-V2G5T.pdf" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 16 16">
    <path fill="#00857C" d="M2.556 3.894v9.326h10.888V3.894H15v9.326c0 .863-.7 1.555-1.556 1.555H2.556A1.555 1.555 0 0 1 1 13.22V3.894h1.556zM8.924.775v8.59L10.9 7.391l1.1 1.1-3.85 3.85-3.85-3.85 1.1-1.1 1.974 1.974V.775h1.551z" />
</svg>
 Save</a>
                                                        </div>
                        
                        <div class="news-item-text-container">
                            <p class="date-text">
                                January 21, 2020 6:55 am ET                            </p>
                            <p class="bwalignc"> Submission Based on PROfound, the First Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients </p>
<p>KENILWORTH, N.J.&#8211;(<a target="_blank" href="http://www.businesswire.com/" rel="noopener">BUSINESS WIRE</a>)&#8211;AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent.
</p>
<p>
A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020.
</p>
<p>
The sNDA acceptance for review by the FDA is based on positive results from the Phase 3 PROfound trial, which were presented during a Presidential Symposium at the 2019 European Society of Medical Oncology congress.
</p>
<p>
Results of the PROfound trial showed LYNPARZA met its primary endpoint, significantly reducing the risk of radiographic disease progression or death by 66% in patients with <i>BRCA</i>1/2 or <i>ATM</i>-mutated mCRPC and improved radiographic progression-free survival (rPFS) to a median of 7.4 months vs. 3.6 months for patients receiving abiraterone or enzalutamide (HR 0.34 [95% CI, 0.25-0.47], p&lt;0.0001).
</p>
<p>
The trial also met the key secondary endpoint of rPFS in the overall population of men with HRR-mutated (HRRm) mCRPC (those with mutations in <i>BRCA</i>1/2, <i>ATM</i>, <i>CDK12</i> or 11 other HRRm genes), where LYNPARZA reduced the risk of radiographic disease progression or death by 51% and improved rPFS to a median of 5.8 months vs. 3.5 months for those receiving abiraterone or enzalutamide (HR 0.49 [95% CI, 0.38-0.63], p&lt;0.0001).
</p>
<p>
The safety and tolerability profile of LYNPARZA in the PROfound trial did not differ from that observed in prior clinical trials. The most common adverse events (AEs) ≥20% for LYNPARZA compared to abiraterone or enzalutamide were anemia (47% vs.15%), nausea (41% vs. 19%), fatigue and asthenia (41% vs. 32%), decreased appetite (30% vs. 18%) and diarrhea (21% vs. 7%). Grade 3 or above AEs were anemia (22% vs. 5%), fatigue and asthenia (3% vs. 5%), vomiting (2% vs. 1%), dyspnea (2% vs. 0%), urinary tract infection (2% vs. 4%), nausea (1% vs. 0%), decreased appetite (1% each), diarrhea (1% vs. 0%) and back pain (1% vs. 2%). AEs led to dose interruptions in 22% of patients on LYNPARZA vs. 4% of patients on abiraterone and enzalutamide and discontinuation of treatment in 16% of patients on LYNPARZA vs. 9% on abiraterone and enzalutamide.
</p>
<p>
PROfound is the first Phase 3 trial evaluating a targeted treatment in biomarker-selected prostate cancer patients. LYNPARZA, which is being jointly developed and commercialized by AstraZeneca and Merck, was most recently approved in the U.S. on Dec. 27, 2019, as a first-line maintenance treatment for germline <i>BRCA</i>-mutated (g<i>BRCA</i>m) metastatic pancreatic cancer that has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. It is also approved in the U.S. as a first-line maintenance treatment in <i>BRCA-</i>mutated advanced ovarian cancer following response to platinum-based chemotherapy and for the treatment of g<i>BRCA</i>m HER2-negative metastatic breast cancer patients previously treated with chemotherapy.
</p>
<p>
<b>About PROfound</b>
</p>
<p>
PROfound is a prospective, multi-center, randomized, open-label, Phase 3 trial evaluating the efficacy and safety of LYNPARZA vs. new hormonal agents (e.g. abiraterone or enzalutamide) in patients with mCRPC who have progressed on prior treatment with a new hormonal anticancer treatment and have a qualifying tumor mutation in one of 15 genes involved in the homologous recombination repair (HRR) pathway, among them <i>BRCA</i>1/2, <i>ATM</i> and <i>CDK12</i>.
</p>
<p>
The trial was designed to analyze patients with HRRm genes in two cohorts: the primary endpoint was in those with mutations in <i>BRCA</i>1/2 or <i>ATM</i> genes and then, if LYNPARZA showed clinical benefit, a formal analysis was performed of the overall trial population of patients with HRRm genes (<i>BRCA</i>1/2, <i>ATM</i>, <i>CDK12</i> and 11 other HRRm genes; key secondary endpoint).
</p>
<p>
<b>IMPORTANT SAFETY INFORMATION</b>
</p>
<p>
<b>CONTRAINDICATIONS</b>
</p>
<p>
There are no contraindications for LYNPARZA.
</p>
<p>
<b>WARNINGS AND PRECAUTIONS</b>
</p>
<p>
<b>Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): </b>Occurred in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The duration of therapy in patients who developed secondary MDS/AML varied from &lt;6 months to &gt;2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy, and some also had a history of more than one primary malignancy or of bone marrow dysplasia.
</p>
<p>
Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.
</p>
<p>
If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.
</p>
<p>
<b>Pneumonitis: </b>Occurred in &lt;1% of patients exposed to LYNPARZA, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.
</p>
<p>
<b>Embryo-Fetal Toxicity: </b>Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.
</p>
<p>
<i>Females</i>
</p>
<p>
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.
</p>
<p>
<i>Males</i>
</p>
<p>
Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.
</p>
<p>
<b>ADVERSE REACTIONS—First-Line Maintenance <i>BRCA</i>m Advanced Ovarian Cancer</b>
</p>
<p>
Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA in the <b>first-line maintenance setting</b> for <b>SOLO-1 </b>were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/ nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia (11%), and stomatitis (11%).
</p>
<p>
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the <b>first-line maintenance setting for SOLO-1</b> were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).
</p>
<p>
<b>ADVERSE REACTIONS—Maintenance Recurrent Ovarian Cancer</b>
</p>
<p>
Most common adverse reactions (Grades 1-4) in ≥20% of patients in clinical trials of LYNPARZA in the <b>maintenance setting </b>for <b>SOLO-2</b> were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis/upper respiratory tract infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).
</p>
<p>
<b>Study 19: </b>nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%), and dyspepsia (20%).
</p>
<p>
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2/Study 19</b>) were: increase in mean corpuscular volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute neutrophil count (51%/47%), increase in serum creatinine (44%/45%), and decrease in platelets (42%/36%).
</p>
<p>
<b>ADVERSE REACTIONS—Advanced g<i>BRCA</i>m Ovarian Cancer</b>
</p>
<p>
Most common adverse reactions (Grades 1-4) in ≥20% of patients in clinical trials of LYNPARZA for <b>advanced g<i>BRCA</i>m ovarian cancer after 3 or more lines of chemotherapy </b>(pooled from 6 studies) were: fatigue/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis/upper respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and arthralgia/musculoskeletal pain (21%).
</p>
<p>
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA for <b>advanced g<i>BRCA</i>m ovarian cancer </b>(pooled from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular volume elevation (57%), decrease in lymphocytes (56%), increase in serum creatinine (30%), decrease in platelets (30%), and decrease in absolute neutrophil count (25%).
</p>
<p>
<b>ADVERSE REACTIONS—g<i>BRCA</i>m, HER2-negative Metastatic Breast Cancer</b>
</p>
<p>
Most common adverse reactions (Grades 1-4) in ≥20% of patients in <b>OlympiAD</b> were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).
</p>
<p>
Most common laboratory abnormalities (Grades 1-4) in <span class="bwuline">&gt;</span>25% of patients in <b>OlympiAD </b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).
</p>
<p>
<b>ADVERSE REACTIONS—First-Line Maintenance g<i>BRCA</i>m Metastatic Pancreatic Adenocarcinoma</b>
</p>
<p>
Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA in the <b>first-line maintenance setting</b> for <b>POLO </b>were: fatigue (60%), nausea (45%), abdominal pain (34%), diarrhea (29%), anemia (27%), decreased appetite (25%), constipation (23%), vomiting (20%), back pain (19%), arthralgia (15%), rash (15%), thrombocytopenia (14%), dyspnea (13%), neutropenia (12%), nasopharyngitis (12%), dysgeusia (11%), and stomatitis (10%).
</p>
<p>
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for POLO were: increase in serum creatinine (99%), decrease in hemoglobin (86%), increase in mean corpuscular volume (71%), decrease in lymphocytes (61%), decrease in platelets (56%), decrease in leukocytes (50%), and decrease in absolute neutrophil count (25%).
</p>
<p>
<b>DRUG INTERACTIONS</b>
</p>
<p>
<b>Anticancer Agents: </b>Clinical studies of LYNPARZA in combination with other myelosuppressive anticancer agents, including DNA-damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.
</p>
<p>
<b>CYP3A Inhibitors: </b>Avoid concomitant use of strong or moderate CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be co-administered, reduce the dose of LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during LYNPARZA treatment.
</p>
<p>
<b>CYP3A Inducers: </b>Avoid concomitant use of strong or moderate CYP3A inducers when using LYNPARZA. If a moderate inducer cannot be avoided, there is a potential for decreased efficacy of LYNPARZA.
</p>
<p>
<b>USE IN SPECIFIC POPULATIONS</b>
</p>
<p>
<b>Lactation: </b>No data are available regarding the presence of olaparib in human milk, its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infant, advise a lactating woman not to breastfeed during treatment with LYNPARZA and for 1 month after receiving the final dose.
</p>
<p>
<b>Pediatric Use: </b>The safety and efficacy of LYNPARZA have not been established in pediatric patients.
</p>
<p>
<b>Hepatic Impairment: </b>No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C).
</p>
<p>
<b>Renal Impairment: </b>No dosage modification is recommended in patients with mild renal impairment (CLcr 51-80 mL/min estimated by Cockcroft-Gault). In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min).
</p>
<p>
<b>INDICATIONS</b>
</p>
<p>
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
</p>
<p>
<b>First-Line Maintenance <i>BRCA</i>m Advanced Ovarian Cancer</b>
</p>
<p>
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic <i>BRCA</i>-mutated (g<i>BRCA</i>m<i> </i>or s<i>BRCA</i>m) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
</p>
<p>
<b>Maintenance Recurrent Ovarian Cancer</b>
</p>
<p>
For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
</p>
<p>
<b>Advanced g<i>BRCA</i>m Ovarian Cancer</b>
</p>
<p>
For the treatment of adult patients with deleterious or suspected deleterious germline <i>BRCA-</i>mutated (g<i>BRCA</i>m) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
</p>
<p>
<b>g<i>BRCA</i>m, HER2-negative Metastatic Breast Cancer</b>
</p>
<p>
In patients with deleterious or suspected deleterious g<i>BRCA</i>m<i>, </i>human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
</p>
<p>
<b>First-Line Maintenance g<i>BRCA</i>m Metastatic Pancreatic Cancer</b>
</p>
<p>
For the maintenance treatment of adult patients with deleterious or suspected deleterious g<i>BRCA</i>m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
</p>
<p>
<b>Please <a href="https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf" rel="nofollow" shape="rect">click here for complete Prescribing Information, including Patient Information (Medication Guide)</a>.</b>
</p>
<p>
<b>About Metastatic Castration-Resistant Prostate Cancer (mCRPC)</b>
</p>
<p>
Prostate cancer is the second-most common cancer in men and is associated with a significant mortality rate. In the U.S. this year, it is estimated that more than 191,000 people will be diagnosed with prostate cancer and more than 33,000 people will die of this disease. More than one in four patients with mCRPC harbor an HRR mutation.
</p>
<p>
Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone. mCRPC occurs when prostate cancer grows and spreads to other parts of the body despite the use of androgen-deprivation therapy to block the action of male sex hormones. Approximately 10-20% of men with advanced prostate cancer will develop CRPC within five years, and at least 84% of these will have metastases at the time of CRPC diagnosis. Of men with no metastases at CRPC diagnosis, 33% are likely to develop metastases within two years. Despite an increase in the number of available therapies, five-year survival for men with mCRPC remains low.
</p>
<p>
<b>About Homologous Recombination Repair (HRR) Mutations</b>
</p>
<p>
Homologous recombination repair (HRR) plays a significant role in maintaining the genetic stability of cells and suppressing tumor growth by repairing damaged DNA. Mutations, or defects, in homologous recombination (HR) pathway genes – which include ataxia telangiectasia mutated (<i>ATM</i>) and <i>BRCA</i>1/2 genes – increase the risk for breast, ovarian, pancreatic, prostate and other cancers.
</p>
<p>
<b>About LYNPARZA<sup>®</sup> (olaparib)</b>
</p>
<p>
LYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as <i>BRCA</i> mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. LYNPARZA is being tested in a range of tumor types with defects and dependencies in the DDR.
</p>
<p>
LYNPARZA, which is being jointly developed and commercialized by AstraZeneca and Merck, has a broad and advanced clinical trial development program, and AstraZeneca and Merck are working together to understand how it may affect multiple PARP-dependent tumors as a monotherapy and in combination across multiple cancer types.
</p>
<p>
<b>About the AstraZeneca and Merck Strategic Oncology Collaboration</b>
</p>
<p>
In July 2017, AstraZeneca and Merck &amp; Co., Inc., Kenilworth, NJ, US, known as MSD outside the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialize LYNPARZA, the world’s first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. Working together, the companies will develop LYNPARZA and selumetinib in combination with other potential new medicines and as monotherapies. Independently, the companies will develop LYNPARZA and selumetinib in combination with their respective PD-L1 and PD-1 medicines.
</p>
<p>
<b>Merck’s Focus on Cancer</b>
</p>
<p>
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit <a href="http://www.merck.com/clinicaltrials" rel="nofollow" shape="rect">www.merck.com/clinicaltrials</a>.
</p>
<p>
<b>About Merck</b>
</p>
<p>
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world &#8211; including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit <a href="http://www.merck.com/index.html" rel="nofollow" shape="rect">www.merck.com</a> and connect with us on <a href="https://twitter.com/Merck" rel="nofollow" shape="rect">Twitter</a>, <a href="https://www.facebook.com/MerckInvents/" rel="nofollow" shape="rect">Facebook</a>, <a href="https://www.instagram.com/merck/" rel="nofollow" shape="rect">Instagram</a>, <a href="https://www.youtube.com/Merck" rel="nofollow" shape="rect">YouTube</a> and <a href="https://www.linkedin.com/company/merck" rel="nofollow" shape="rect">LinkedIn</a>.
</p>
<p>
<b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA</b>
</p>
<p>
This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
</p>
<p>
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
</p>
<p>
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (<a href="https://www.sec.gov/" rel="nofollow" shape="rect">www.sec.gov</a>).
</p>
<p>
<img alt="" src="https://www.businesswire.com/images/spacer.gif" style="width:0;height:0"><br />
<span class="bwct31415"><br />
</span></p>
<p> Media: </p>
<p>Pamela Eisele <br />(267) 305-3558 </p>
<p>Steve Wanczyk <br />(267) 305-5563 </p>
<p>Investors: </p>
<p>Peter Dannenbaum <br />(908) 740-1037 </p>
<p>Courtney Ronaldo <br />(908) 740-6132 </p>
                        </div>
                        
                    </div>      

                                            <div id="sidebar-news" class="sidebar">
                            
                            <h2>Multimedia</h2>                                        <img src="https://s2.q4cdn.com/584635680/files/doc_events/2020/01/1/merck_logo.jpg" title="Merck Logo" style="max-width: 10rem;" />
                                        <br/>
                                        <a href="https://s2.q4cdn.com/584635680/files/doc_events/2020/01/1/merck_logo.jpg" target="_blank" title="Merck Logo">Merck Logo</a> <span class="text-descriptive">(21 KB)</span>
                                        <br/>
                                                            </div>
                                    </div><!-- .entry-content -->
                <div class="opt-in-communication-wrapper wrapper no-secondary-image" id="opt-in-communication-block-block_5e949a66cfcc9" aria-hidden="true">

                    <div class="opt-in-communication-block img-wrapper" style="position: relative;">
                        <picture class="opt-in-primary-img">
                            <source media="(max-width: 767px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=321,196">
                            <source media="(min-width: 768px) and (max-width: 1279px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=656,432">
                            <source media="(min-width: 1280px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=516,596">
                            <img class="opt-in-primary-img lazyload" loading="lazy" src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=516,596" alt="opt-in primary image"/>
                        </picture>
                    </div>

                    <div class="opt-in-left">
                        <div class="opt-in-left-content">
                                <h2 class="opt-in-title">Sign up for email alerts</h2>
                            <p class="opt-in-caption"></p>
                        </div>
                        <div class="opt-in-communication-block-iframe-holder">
                            <iframe id="opt-in-communication-block-block_5e949a66cfcc9-iFrame" src="https://merck2016rd.q4web.com/Email-Signup-New-Release/" style="width: 100%; overflow: hidden; height: 491px;" scrolling="no" frameborder="0"></iframe>
                            <script>
                                try {
                                    function iFrameResizerDefer(method) { if (typeof iFrameResize === "function") { method(); } else { setTimeout(function() { iFrameResizerDefer(method) }, 50); } }
                                    document.getElementById('opt-in-communication-block-block_5e949a66cfcc9-iFrame').onload = function() { iFrameResize({log:false}); };
                                } catch(ex) {
                                    console.log(ex);
                                } 
                            </script>

                        </div>
                    </div>

                </div>
                <p class="wrapper"><a href="https://www.merck.com/investor-relations/email-alerts/" class="btn secondary">Unsubscribe from email alerts</a></p>
                <footer class="entry-footer">
                                    </footer><!-- .entry-footer -->
            </article><!-- #post-744019 -->
		
        </main><!-- #main -->
	</div><!-- #primary -->
    
    <div class="related-content-container">
        <h4>Related links</h4>
        <div class="related-content-section">
            <div class="related-content-item">
                <a href="https://www.merck.com/media/company-statements/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png" alt="related content image #1"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Company Statements</strong></p>
                        <p class="realted-content-excerpt">Read our latest company statements.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="https://www.merck.com/media/media-library/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png" alt="related content image #2"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Media library</strong></p>
                        <p class="realted-content-excerpt">Access videos, logos, photos, and infographics.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="https://www.merck.com/company-overview/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png" alt="related content image #3"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>About Merck</strong></p>
                        <p class="realted-content-excerpt">We are committed to providing leading innovations for today and the future that save and improve lives around the world.</p>
                    </div>
                </a>
            </div>
        </div>
    </div>

</div><!-- #content -->
<footer id="footerMain" class="footer">
    <div id="footerSocial">
        <div class="wrapper">
            <h3>Connect with us on social</h3>
            <div class="social-icons">
                                    <a href="https://twitter.com/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/twitter-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.facebook.com/MerckInvents" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/facebook-f-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.linkedin.com/company/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/linkedin-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.instagram.com/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/instagram-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.youtube.com/user/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/youtube-brands.svg" alt="social icon" />
                    </a>
                            </div>
        </div>
    </div>
    <div class="wrapper">
        <div id="footerPrograms">
                            <div class="column col-one">
                    <input type="checkbox" id="columnOne" class="checkbox-toggle">
                    <label for="columnOne" class="column-header">For patients and health care professionals</label>
                    <ul>
                        <li><a href="https://www.merckhelps.com/" target="_blank" rel="noopener">MerckHelps</a><br>
                            Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients</li>
                        <li><a href="https://www.merckaccessprogram.com/" target="_blank" rel="noopener">Merck Access Program</a><br>
                            Information about insurance coverage and financial assistance options for eligible patients</li>
                        <li><a href="https://www.merckclinicaltrials.com/" target="_blank" rel="noopener">Clinical trials</a><br>
                            Learn about our clinical trials and find available studies</li>
                        <li><a href="https://www.merckmanuals.com/" target="_blank" rel="noopener">Merck Manuals</a><br>
                            Medical information source covering thousands of topics in all fields of medicine</li>
                    </ul>
                </div>
            
                            <div class="column col-two">
                    <input type="checkbox" id="columnTwo" class="checkbox-toggle">
                    <label for="columnTwo" class="column-header">Environmental, Social &amp; Governance (ESG)</label>
                    <ul>
                                                    <li>
                                <a href="https://www.merck.com/company-overview/esg/" target="_blank" rel="noopener">Environmental, Social &amp; Governance (ESG) Report</a>
                                                                    <br />
                                    Reporting on our commitment to operating responsibly to benefit society                                                            </li>
                                                    <li>
                                <a href="https://www.merckformothers.com/" target="_blank" rel="noopener">Merck for Mothers</a>
                                                                    <br />
                                    An initiative to create a world where no woman has to die giving life                                                            </li>
                                            </ul>
                </div>
            
                            <div class="column col-three">
                    <input type="checkbox" id="columnThree" class="checkbox-toggle">
                    <label for="columnThree" class="column-header">About Merck</label>
                    <ul>
                        <li><a href="https://www.merck-animal-health.com/" target="_blank" rel="noopener">Merck Animal Health</a><br>
                            The global animal health business unit of Merck</li>
                        <li><a href="https://horizonblue.sapphiremrfhub.com/tocs/current/merck-co-inc" target="_blank" rel="noopener">Health Plan - Transparency in Coverage</a><br>
                            In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.</li>
                    </ul>
                </div>
                    </div>
        <div id="footerCopyrightLogos">
            <div id="footerCopyright">
                		<div class="menu-footer-menu-container"><ul id="menuFooter" class="footer-links"><li id="menu-item-674051" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-674051"><a href="https://www.merck.com/forward-looking-statement/">Forward-looking statement</a></li>
<li id="menu-item-137027" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137027"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/cookie-privacy-policy.html">Cookie policy</a></li>
<li id="menu-item-763862" class="ot-sdk-show-settings menu-item menu-item-type-custom menu-item-object-custom menu-item-763862"><a href="#">Cookie Preferences</a></li>
<li id="menu-item-137025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137025"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/index.html">Privacy</a></li>
<li id="menu-item-137028" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137028"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/transparency-and-privacy.html">Transparency disclosure</a></li>
<li id="menu-item-669400" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669400"><a href="https://www.merck.com/terms-of-use/">Terms of use</a></li>
<li id="menu-item-3374425" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3374425"><a href="https://www.msdaccessibility.com/">Accessibility</a></li>
<li id="menu-item-669401" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669401"><a href="https://www.merck.com/sitemap/">Sitemap</a></li>
</ul></div>                <small>
                    Copyright © 2022  <a href="https://www.myknot.club/">MyKnot</a>; Co., India and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.                h-merck-mco-theme/images/logo.jpeg"         </small>
            </div>
            <div id="footerLogos">
                                <a href="https://www.essentialaccessibility.com/merck/?utm_source=merckhomepage&amp;utm_medium=iconlarge&amp;utm_term=eachannelpage&amp;utm_content=header&amp;utm_campaign=merck" target="_blank" rel="noopener">
                    <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/accessibility.png" alt="Accessibility icon" />
                </a>
                <!-- Truste badges -->
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" alt="View Privacy Shield Verification Status" />
                </a>
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" alt="View APEC CBPR Privacy Certification Status" />
                </a>
            </div>
        </div>
    </div>
</footer><!-- #footerMain -->
</div><!-- #page -->
<div id="fowardGuidanceModel" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA</h3>

            <div class="forward-guidance-content">
                <p>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<br><br>

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.<br><br>

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).<br><br>

<b>No Duty to Update</b><br>

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

</p>            </div>

            <div class="btn-container text-center">
                <a href="https://www.merck.com/" class="btn tertiary">Decline</a>
                <a href="javascript:void()" class="btn tertiary negative" title="" onclick="sessionStorage.setItem('guidance-accepted', JSON.stringify(true)); document.getElementById('fowardGuidanceModel').style.display = 'none';">Accept</a>
            </div>

        </div>
    </div>
</div>
<link rel='stylesheet' id='related-content-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/related-content-section.min.css?ver=5.9.4' media='all' />
<script defer="defer" src='https://www.merck.com/wp-content/plugins/mhh-corporateberg/opt-in-communication-block/js/iframeResizer.min.js?ver=5.9.4' id='iframe-resize-js-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/plugins.min.js?ver=20190301' id='Mco-plugins-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/scripts.min.js?ver=20190301' id='Mco-scripts-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/search_suggestions.min.js?ver=1664904127' id='search_suggestion-js'></script>
<div id="externalLinkModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3 id="externalLinkModalTitle">You are leaving Merck.com</h3>

            <div class="forward-guidance-content">
                <p id="externalLinkModalMessage" style="max-width: 31.25rem;"></p>
            </div>
            
            <div class="btn-container text-center">
                <button class="btn tertiary" id="externalLinkCancelBtn" title="" onclick="document.getElementById('externalLinkModal').style.display = 'none';">Cancel</button>
                <a href="#" target="_blank" class="btn tertiary negative" id="externalLinkModalBtn">Continue</a>
            </div>
        
        </div>
    </div>
</div>

<script type="text/javascript">
    let whitelist_domains =  ".local,merck-go-vip,merck-develop.go-vip.co/merck,merck-preprod.go-vip.co/merck,vip-msd.com/merck,merck.com,q4cdn.com,cloudfront.net,wpvip-safety-data-sheets.s3.amazonaws.com,google.com/calendar,outlook.live.com/calendar,calendar.yahoo.com,merckhelps.com,merckaccessprogram.com,merckmanuals.com,merckconnect.com,merckclinicaltrials.com,merck-animal-health.com,merckformothers.com,mrknewsroom.com,facebook.com,twitter.com,linkedin.com,mailto:,javascript:,tel:";
    let whitelist_domains_array = whitelist_domains.split(',');
    whitelist_domains_array.unshift(document.location.hostname);
        // External Links
    try {
        let links = Array.from(document.links);
        for (let i = 0; i < links.length; i++) {
            let link = links[i];
            if (!shouldWhitelistDomain(link.href)) {
                link.addEventListener("click", function (e) {
                    e.preventDefault();
                    let modal_data = getLinkContent(link.href);
                    document.getElementById('externalLinkModalTitle').textContent = modal_data.title;
                    document.getElementById('externalLinkModalMessage').textContent = modal_data.message;
                    document.getElementById('externalLinkModalBtn').href = this.href;
                    document.getElementById('externalLinkModalBtn').setAttribute('onclick', 'document.getElementById(\'externalLinkModal\').style.display = "none";');
                    document.getElementById('externalLinkModal').style.display = document.getElementById('externalLinkModal').style.display === 'none' ? 'block' : 'none';
                    
                    if (modal_data.cancelBtnText){
                        document.getElementById('externalLinkCancelBtn').textContent = modal_data.cancelBtnText;

                    }
                    if (modal_data.continueBtnText){
                        document.getElementById('externalLinkModalBtn').textContent = modal_data.continueBtnText;
                    }
                });
            }
        }
    } catch(ex) {
        console.log(ex);
    }

    function getLinkContent(link) {
        try {
            let title = htmlDecode("You are leaving Merck.com");
            let message = htmlDecode("The link you have selected will direct you to a site outside of www.merck.com. We are Merck &amp; Co. Inc., Rahway, NJ, USA known as MSD outside the United States and Canada. ");
            let cancelBtnText = htmlDecode("");
            let continueBtnText = htmlDecode("");
                        data = {
                title: title,
                message: message,
                cancelBtnText: cancelBtnText,
                continueBtnText: continueBtnText
            }
            return data;
        }
        catch(ex) {
            console.log(ex);
        }
    }

    function htmlDecode(input){
        if (input === '') return '';
        var e = document.createElement('div');
        e.innerHTML = input;
        return e.childNodes[0].nodeValue;
    }

    function shouldWhitelistDomain(link){
        return whitelist_domains_array.some(domain => new RegExp(domain).test(link));
    }
</script>
<div id="ukUserModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Welcome to Merck.com</h3>

            <div class="forward-guidance-content">
                <p style="max-width: 31.25rem;">By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.</p>
            </div>

            <div class="btn-container text-center">
                <a target="_blank" class="btn tertiary negative" id="externalLinkModalBtn" onclick="AcceptUKMessage();">Continue</a>
            </div>

        </div>
    </div>
</div>

<script type="text/javascript">
    function AcceptUKMessage() {
        try {
            let accepted = {
                expire: new Date(new Date().getTime() + 60 * 60 * 24 * 1000)
            };
            sessionStorage.setItem('uk-messaging', JSON.stringify(accepted));
            document.getElementById('ukUserModal').style.display = 'none';
        } catch (ex) {
            console.log(ex);
        }
    }
</script>

<script>console.log("US");</script><script>
		utag_data.page_datepublished = "2020-01-21 06:55:00";
	utag_data.page_datemodified = "2022-10-04 00:06:22";
	dataLayer.push(utag_data);
</script>

	<!-- OneTrust Cookies Consent Notice start -->
	<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js"  type="text/javascript" charset="UTF-8" data-domain-script="fd658a96-8c4a-4c03-973e-fd83f98fa618"></script>
	<script type="text/javascript">
		function OptanonWrapper() { }
	</script>
	<!-- OneTrust Cookies Consent Notice end -->
	<script type="text/javascript">
                        /*
* FileSaver.js
* A saveAs() FileSaver implementation.
*
* By Eli Grey, http://eligrey.com
*
* License : https://github.com/eligrey/FileSaver.js/blob/master/LICENSE.md (MIT)
* source  : http://purl.eligrey.com/github/FileSaver.js
*/

// The one and only way of getting global scope in all environments
// https://stackoverflow.com/q/3277182/1008999
var _global = typeof window === 'object' && window.window === window
  ? window : typeof self === 'object' && self.self === self
  ? self : typeof global === 'object' && global.global === global
  ? global
  : this

function bom (blob, opts) {
  if (typeof opts === 'undefined') opts = { autoBom: false }
  else if (typeof opts !== 'object') {
    console.warn('Deprecated: Expected third argument to be a object')
    opts = { autoBom: !opts }
  }

  // prepend BOM for UTF-8 XML and text/* types (including HTML)
  // note: your browser will automatically convert UTF-16 U+FEFF to EF BB BF
  if (opts.autoBom && /^\s*(?:text\/\S*|application\/xml|\S*\/\S*\+xml)\s*;.*charset\s*=\s*utf-8/i.test(blob.type)) {
    return new Blob([String.fromCharCode(0xFEFF), blob], { type: blob.type })
  }
  return blob
}

function download (url, name, opts) {
  var xhr = new XMLHttpRequest()
  xhr.open('https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/GET', url)
  xhr.responseType = 'blob'
  xhr.onload = function () {
    saveAs(xhr.response, name, opts)
  }
  xhr.onerror = function () {
    console.error('could not download file')
  }
  xhr.send()
}

function corsEnabled (url) {
  var xhr = new XMLHttpRequest()
  // use sync to avoid popup blocker
  xhr.open('https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/HEAD', url, false)
  try {
    xhr.send()
  } catch (e) {}
  return xhr.status >= 200 && xhr.status <= 299
}

// `a.click()` doesn't work for all browsers (#465)
function click (node) {
  try {
    node.dispatchEvent(new MouseEvent('click'))
  } catch (e) {
    var evt = document.createEvent('MouseEvents')
    evt.initMouseEvent('click', true, true, window, 0, 0, 0, 80,
                          20, false, false, false, false, 0, null)
    node.dispatchEvent(evt)
  }
}

// Detect WebView inside a native macOS app by ruling out all browsers
// We just need to check for 'Safari' because all other browsers (besides Firefox) include that too
// https://www.whatismybrowser.com/guides/the-latest-user-agent/macos
var isMacOSWebView = /Macintosh/.test(navigator.userAgent) && /AppleWebKit/.test(navigator.userAgent) && !/Safari/.test(navigator.userAgent)

var saveAs = _global.saveAs || (
  // probably in some web worker
  (typeof window !== 'object' || window !== _global)
    ? function saveAs () { /* noop */ }

  // Use download attribute first if possible (#193 Lumia mobile) unless this is a macOS WebView
  : ('download' in HTMLAnchorElement.prototype && !isMacOSWebView)
  ? function saveAs (blob, name, opts) {
    var URL = _global.URL || _global.webkitURL
    var a = document.createElement('a')
    name = name || blob.name || 'download'

    a.download = name
    a.rel = 'noopener' // tabnabbing

    // TODO: detect chrome extensions & packaged apps
    // a.target = '_blank'

    if (typeof blob === 'string') {
      // Support regular links
      a.href = blob
      if (a.origin !== location.origin) {
        corsEnabled(a.href)
          ? download(blob, name, opts)
          : click(a, a.target = '_blank')
      } else {
        click(a)
      }
    } else {
      // Support blobs
      a.href = URL.createObjectURL(blob)
      setTimeout(function () { URL.revokeObjectURL(a.href) }, 4E4) // 40s
      setTimeout(function () { click(a) }, 0)
    }
  }

  // Use msSaveOrOpenBlob as a second approach
  : 'msSaveOrOpenBlob' in navigator
  ? function saveAs (blob, name, opts) {
    name = name || blob.name || 'download'

    if (typeof blob === 'string') {
      if (corsEnabled(blob)) {
        download(blob, name, opts)
      } else {
        var a = document.createElement('a')
        a.href = blob
        a.target = '_blank'
        setTimeout(function () { click(a) })
      }
    } else {
      navigator.msSaveOrOpenBlob(bom(blob, opts), name)
    }
  }

  // Fallback to using FileReader and a popup
  : function saveAs (blob, name, opts, popup) {
    // Open a popup immediately do go around popup blocker
    // Mostly only available on user interaction and the fileReader is async so...
    popup = popup || open('', '_blank')
    if (popup) {
      popup.document.title =
      popup.document.body.innerText = 'downloading...'
    }

    if (typeof blob === 'string') return download(blob, name, opts)

    var force = blob.type === 'application/octet-stream'
    var isSafari = /constructor/i.test(_global.HTMLElement) || _global.safari
    var isChromeIOS = /CriOS\/[\d]+/.test(navigator.userAgent)

    if ((isChromeIOS || (force && isSafari) || isMacOSWebView) && typeof FileReader !== 'undefined') {
      // Safari doesn't allow downloading of blob URLs
      var reader = new FileReader()
      reader.onloadend = function () {
        var url = reader.result
        url = isChromeIOS ? url : url.replace(/^data:[^;]*;/, 'data:attachment/file;')
        if (popup) popup.location.href = url
        else location = url
        popup = null // reverse-tabnabbing #460
      }
      reader.readAsDataURL(blob)
    } else {
      var URL = _global.URL || _global.webkitURL
      var url = URL.createObjectURL(blob)
      if (popup) popup.location = url
      else location.href = url
      popup = null // reverse-tabnabbing #460
      setTimeout(function () { URL.revokeObjectURL(url) }, 4E4) // 40s
    }
  }
)

_global.saveAs = saveAs.saveAs = saveAs

if (typeof module !== 'undefined') {
  module.exports = saveAs;
}

/*! ics.js Wed Sept 14 2017 */
var ics=function(e,t){"use strict";{if(!(navigator.userAgent.indexOf("MSIE")>-1&&-1==navigator.userAgent.indexOf("MSIE 10"))){void 0===e&&(e="default"),void 0===t&&(t="Calendar");var r=-1!==navigator.appVersion.indexOf("Win")?"\r\n":"\n",n=[],i=["BEGIN:VCALENDAR","PRODID:"+t,"VERSION:2.0"].join(r),o=r+"END:VCALENDAR",a=["SU","MO","TU","WE","TH","FR","SA"];return{events:function(){return n},calendar:function(){return i+r+n.join(r)+o},addEvent:function(t,i,o,l,u,s){if(void 0===t||void 0===i||void 0===o||void 0===l||void 0===u)return!1;if(s&&!s.rrule){if("YEARLY"!==s.freq&&"MONTHLY"!==s.freq&&"WEEKLY"!==s.freq&&"DAILY"!==s.freq)throw"Recurrence rrule frequency must be provided and be one of the following: 'YEARLY', 'MONTHLY', 'WEEKLY', or 'DAILY'";if(s.until&&isNaN(Date.parse(s.until)))throw"Recurrence rrule 'until' must be a valid date string";if(s.interval&&isNaN(parseInt(s.interval)))throw"Recurrence rrule 'interval' must be an integer";if(s.count&&isNaN(parseInt(s.count)))throw"Recurrence rrule 'count' must be an integer";if(void 0!==s.byday){if("[object Array]"!==Object.prototype.toString.call(s.byday))throw"Recurrence rrule 'byday' must be an array";if(s.byday.length>7)throw"Recurrence rrule 'byday' array must not be longer than the 7 days in a week";s.byday=s.byday.filter(function(e,t){return s.byday.indexOf(e)==t});for(var c in s.byday)if(a.indexOf(s.byday[c])<0)throw"Recurrence rrule 'byday' values must include only the following: 'SU', 'MO', 'TU', 'WE', 'TH', 'FR', 'SA'"}}var g=new Date(l),d=new Date(u),f=new Date,S=("0000"+g.getFullYear().toString()).slice(-4),E=("00"+(g.getMonth()+1).toString()).slice(-2),v=("00"+g.getDate().toString()).slice(-2),y=("00"+g.getHours().toString()).slice(-2),A=("00"+g.getMinutes().toString()).slice(-2),T=("00"+g.getSeconds().toString()).slice(-2),b=("0000"+d.getFullYear().toString()).slice(-4),D=("00"+(d.getMonth()+1).toString()).slice(-2),N=("00"+d.getDate().toString()).slice(-2),h=("00"+d.getHours().toString()).slice(-2),I=("00"+d.getMinutes().toString()).slice(-2),R=("00"+d.getMinutes().toString()).slice(-2),M=("0000"+f.getFullYear().toString()).slice(-4),w=("00"+(f.getMonth()+1).toString()).slice(-2),L=("00"+f.getDate().toString()).slice(-2),O=("00"+f.getHours().toString()).slice(-2),p=("00"+f.getMinutes().toString()).slice(-2),Y=("00"+f.getMinutes().toString()).slice(-2),U="",V="";y+A+T+h+I+R!=0&&(U="T"+y+A+T,V="T"+h+I+R);var B,C=S+E+v+U,j=b+D+N+V,m=M+w+L+("T"+O+p+Y);if(s)if(s.rrule)B=s.rrule;else{if(B="rrule:FREQ="+s.freq,s.until){var x=new Date(Date.parse(s.until)).toISOString();B+=";UNTIL="+x.substring(0,x.length-13).replace(/[-]/g,"")+"000000Z"}s.interval&&(B+=";INTERVAL="+s.interval),s.count&&(B+=";COUNT="+s.count),s.byday&&s.byday.length>0&&(B+=";BYDAY="+s.byday.join(","))}(new Date).toISOString();var H=["BEGIN:VEVENT","UID:"+n.length+"@"+e,"CLASS:PUBLIC","DESCRIPTION:"+i,"DTSTAMP;VALUE=DATE-TIME:"+m,"DTSTART;VALUE=DATE-TIME:"+C,"DTEND;VALUE=DATE-TIME:"+j,"LOCATION:"+o,"SUMMARY;LANGUAGE=en-us:"+t,"TRANSP:TRANSPARENT","END:VEVENT"];return B&&H.splice(4,0,B),H=H.join(r),n.push(H),H},download:function(e,t){if(n.length<1)return!1;t=void 0!==t?t:".ics",e=void 0!==e?e:"calendar";var a,l=i+r+n.join(r)+o;if(-1===navigator.userAgent.indexOf("MSIE 10"))a=new Blob([l]);else{var u=new BlobBuilder;u.append(l),a=u.getBlob("text/x-vCalendar;charset="+document.characterSet)}return saveAs(a,e+t),l},build:function(){return!(n.length<1)&&i+r+n.join(r)+o}}}console.log("Unsupported Browser")}};


function GenerateICS(title, description, start, end) {
    let cal = new ics();
    cal.addEvent(decodeURIComponent(title), decodeURIComponent(description), "", start, end);
    cal.download(decodeURIComponent(title));
}
</script><script>
    /* https://stackoverflow.com/a/26633844/3019650 */
    if (!window.CSS || !CSS.supports('color', 'var(--fake-var)')) {
        (function(a, b, c, d) {
            a = 'https://cdn.jsdelivr.net/npm/css-vars-ponyfill@2';
            b = document;
            c = 'script';
            d = b.createElement(c);
            d.src = a;
            d.type = 'text/java' + c;
            d.async = true;
            a = b.getElementsByTagName(c)[0];
            a.parentNode.insertBefore(d, a);
        })();

        function deferCssVars(method) {
            if (typeof cssVars === "function") {
                method();
            } else {
                setTimeout(function() {
                    deferCssVars(method)
                }, 50);
            }
        }
        deferCssVars(function() {
            cssVars()
        });
    }
</script>
</body>


<!-- Mirrored from www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:41:09 GMT -->
</html>
